Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Real Estate · ·
$20.37
▲ $0.07 (+0.3%)
Market data updated: 09/15 08:22 AM
Fundamentals updated: 09/15/2026
News analyzed: 09/15/2026
Market Cap
$14.05B
Day Range
$20.07 - $20.49
52-Week Range
$15.70 - $22.95
Beta
—
Next Earnings
21.10.2026
DOC is a stock from the Real Estate sector — REITs and real-estate companies — highly sensitive to interest rates and property prices.
+12.7% (1Y)
Strengths: 2/24 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Daily volatility (ATR)
ATR: 2.0% of price
Risk
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: -0.00 (3y annualized return -0.1% / max drawdown 31.7%)
Risk
What to watch next
When today echoes the past.
84/100
Similarity
15
Historical Matches
91/100
Analog Quality
+2.1%
Median 40D Outcome
65/100
Pattern Consistency
🟢 Bullish
53%
+4.4% … +7.7%
🟡 Base
7%
-0.4% … -0.4%
🔴 Bearish
40%
-7.5% … -4.0%
Typical timeframe (based on real historical rates clearing a 60% bar): 40 trading days.
📌 Bottom line: Out of 15 similar historical cases for this stock, 53% (95% CI 30%–75%) saw the stock rise within 20 trading days, with a median gain of +1.1%.
Echo #1 — Trend Acceleration
1 occurrence(s) · 0% historical success
Echo #2 — Oversold Reversal
1 occurrence(s) · 100% historical success
Historical outcome rate is not a probability — it's what happened in this specific historical sample, with a 95% confidence range.
| Horizon | Positive rate (95% CI) | Median | 25th–75th pct | Baseline median |
|---|---|---|---|---|
| 5D | 47% (25%–70%) | +0.8% | -2.7% … +3.4% | +0.1% |
| 10D | 47% (25%–70%) | +0.3% | -3.2% … +3.3% | +0.1% |
| 20D | 53% (30%–75%) | +1.1% | -4.5% … +5.1% | +0.4% |
| 40D | 60% (36%–80%) | +2.1% | -4.2% … +7.9% | +0.7% |
| 60D | 47% (25%–70%) | -1.9% | -7.6% … +11.4% | +0.6% |
Sample size: 15 analogs, each at least 10 trading days apart (no double-counted overlapping events).
What happened after each historical match (20-day return)
| Date | Similarity | Regime | 20D outcome | 60D outcome |
|---|---|---|---|---|
| 2024-12-17 | 84/100 | Consolidation | -0.4% | -1.9% |
| 2021-09-29 | 83/100 | ✓ Consolidation | +4.9% | +3.5% |
| 2017-07-12 | 83/100 | Consolidation | -6.6% | -13.8% |
| 2019-12-10 | 80/100 | Consolidation | +3.1% | -7.2% |
| 2018-10-15 | 80/100 | ✓ Consolidation | +15.4% | +16.1% |
| 2019-07-25 | 80/100 | Consolidation | +8.6% | +17.6% |
| 2019-04-09 | 78/100 | Consolidation | -3.6% | +6.1% |
| 2018-09-12 | 78/100 | Consolidation | -3.1% | +12.2% |
| 2025-04-02 | 78/100 | Consolidation | -11.4% | -12.7% |
| 2025-01-07 | 78/100 | Downtrend | +1.1% | -7.4% |
| 2018-05-24 | 78/100 | Consolidation | +7.4% | +17.1% |
| 2021-01-06 | 77/100 | Consolidation | +5.1% | +10.5% |
| 2024-11-20 | 75/100 | Consolidation | -7.8% | -7.7% |
| 2023-08-11 | 75/100 | ✓ Consolidation | -5.5% | -19.8% |
| 2024-10-11 | 75/100 | Consolidation | +5.0% | -6.2% |
Every accepted match is compared to today across 6 domains (price structure, momentum, technical, volatility, volume, relative strength) using z-scored feature distances — no single indicator dominates. Matches within 10 trading days of each other count as one event, not independent evidence. Outcome rates use a Wilson confidence interval (never a raw percentage alone), the mean return is winsorized against extreme outliers, and "Analog Quality" separately captures sample size, data completeness, and regime match — distinct from raw similarity. Relative strength is measured against SPY and against XLRE (this stock's sector).
Cross-stock analogs — real other companies, not this stock's own history.
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
45
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
50
Value
45
Momentum
26
Risk
50
Sentiment
98
Fundamental
44
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
SCANNING DOC...
Recent media coverage of **Healthpeak Properties** has centered on its financial performance and investor outlook. The company, an S&P 500-listed healthcare-focused REIT, has faced a **3.5% stock decline** since its last earnings report, prompting analysis of future estimates. Analysts like Barclays raised their price target to **$24** while maintaining an equal-weight rating, while CEO Scott Brinker was interviewed about the company’s **700-property portfolio** and strategic focus on healthcare real estate. Comparisons with rival REITs (e.g., EGP) also appeared in investor discussions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Healthpeak Properties. News trend score: 98. Reason: 9 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
21
🎯 Conviction (vs. Emotion)
38
Psychology
71
Fundamentals
44
Technical
26
Valuation
45
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
+1%
Market Narrative
57
Fundamental Reality
38
Narrative Gap
+19
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s extreme anchoring (88) suggests traders are fixating on the 0.6% support level, likely due to its proximity. Despite extreme positive sentiment across all states, weak momentum and neutral RSI imply detached enthusiasm from price action. The narrative gap (22) hints at a disconnect between optimism and fundamentals, raising the question of whether traders are anchoring to recent lows rather than forward-looking catalysts. Overconfidence and loss aversion remain absent, reinforcing a focus on short-term technical thresholds.
Updated: 09/08/2026, 06:09 PM
What could change this?
👥 What the crowd believes
"Q2 2026 13F filings show institutions added shares across 95% of 158 US real estate stocks for over $300M"
"Barclays analyst Richard Hightower raises Healthpeak Properties price target from $23 to $24"
"Healthpeak (DOC) reported earnings 30 days ago... stock is down 3.5%"
📈 7D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 93/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 4/100
🗣️ Why do they disagree?
This stock’s starkly divergent scores reflect a deep divide between methodologies that favor cyclical or contrarian timing and those prioritizing fundamental strength or defensive criteria. Samuel Armstrong Nelson’s high score suggests the stock may be near a cyclical low, aligning with his oversold/overbought framework, while Charles Mackay’s neutral stance implies no obvious speculative frenzy. In contrast, the lowest scores—from Benjamin Graham’s defensive investor, Philip Fisher’s growth focus, and Peter Lynch’s value-growth hybrid—signal fundamental weaknesses, like poor valuation or lack of quality, that would deter disciplined long-term holders. Meanwhile, the middle-ground approaches (like Howard Marks’ market-cycle view or Jack Schwager’s neutral edge) suggest neither a clear buy nor a definitive sell, highlighting uncertainty. The contrast underscores how cyclical traders might see opportunity where value investors see red flags.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 93
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 65
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 53
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 46
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 45
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 43
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 41
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 39
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 38
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 37
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 19
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 18
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 14
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 10
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 9
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 4
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
2.5%
EBITDA Margin
—
ROE
1.0%
ROA
0.4%
ROIC
—
EPS
$0.10
Cash
$467.46M
Total Debt
$9.85B
Current Ratio
—
Debt/Equity
1.31
אין נתונים היסטוריים זמינים.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 17.8.2026 | $0.102 |
| 20.7.2026 | $0.102 |
| 19.7.2026 | $0.102 |
| 15.6.2026 | $0.102 |
| 14.6.2026 | $0.102 |
| 18.5.2026 | $0.102 |
| 17.5.2026 | $0.102 |
| 17.4.2026 | $0.102 |
| 16.4.2026 | $0.102 |
| 17.3.2026 | $0.102 |
| 16.3.2026 | $0.102 |
| 13.2.2026 | $0.102 |
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$10.78
Tangible Book Value per Share (Tangible NAV)
$9.74
Sentiment based on basic keywords (not AI) — 9 positive, 10 neutral, 1 negative out of the last 20 articles.
Yahoo · 14.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 8.9.2026
TMX Newsfile · 8.9.2026
Yahoo · 8.9.2026
Investor's Business Daily · 8.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
MT Newswires · 31.8.2026
Benzinga · 31.8.2026
Yahoo · 28.8.2026
Zacks · 28.8.2026
Zacks · 21.8.2026
SeekingAlpha · 20.8.2026
Yahoo · 17.8.2026
GuruFocus.com · 17.8.2026
Benzinga · 17.8.2026
MT Newswires · 13.8.2026
Healthpeak Properties (DOC) currently has a StockIQ AI score of 45/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
DOC currently scores 45/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
DOC's technical score is 26/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 2.0% of price; Price is above the 200-day average.
Based on the real signals StockIQ computed: Calmar: -0.00 (3y annualized return -0.1% / max drawdown 31.7%); Earnings per share (EPS) growth: -72.2%; Net income growth: -70.7%.
Yes — DOC has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Brinker Scott M | Tax Withholding in Shares | 29.5.2026 | 114 | -114 | $19.15 |
| Brinker Scott M | Grant/Award from Employer | 29.5.2026 | 1,347 | +1,347 | $15.46 |
| Mabry Adam G | Grant/Award from Employer | 29.5.2026 | 625 | +625 | $15.46 |
| Johnston Shawn G | Tax Withholding in Shares | 29.5.2026 | 76 | -76 | $19.15 |
| Mabry Adam G | Tax Withholding in Shares | 29.5.2026 | 43 | -43 | $19.15 |
| Johnston Shawn G | Grant/Award from Employer | 29.5.2026 | 1,358 | +1,358 | $15.46 |
| Moses Kelvin O | Tax Withholding in Shares | 29.5.2026 | 65 | -65 | $19.15 |
| Moses Kelvin O | Grant/Award from Employer | 29.5.2026 | 937 | +937 | $15.46 |
| Patadia Ankit B. | Tax Withholding in Shares | 29.5.2026 | 94 | -94 | $19.15 |
| Patadia Ankit B. | Grant/Award from Employer | 29.5.2026 | 1,358 | +1,358 | $15.46 |
| Thomas John T | Tax Withholding in Shares | 29.5.2026 | 78 | -78 | $19.15 |
| Thomas John T | Grant/Award from Employer | 29.5.2026 | 1,385 | +1,385 | $15.46 |
| Thomas John T | Grant/Award from Employer | 29.5.2026 | 830,053 | +1,385 | $15.46 |
| Thomas John T | Tax Withholding in Shares | 29.5.2026 | 829,975 | -78 | $19.15 |
| Brinker Scott M | Grant/Award from Employer | 29.5.2026 | 214,802 | +1,347 | $15.46 |
| Brinker Scott M | Tax Withholding in Shares | 29.5.2026 | 214,688 | -114 | $19.15 |
| Johnston Shawn G | Grant/Award from Employer | 29.5.2026 | 42,336 | +1,358 | $15.46 |
| Johnston Shawn G | Tax Withholding in Shares | 29.5.2026 | 42,260 | -76 | $19.15 |
| Mabry Adam G | Grant/Award from Employer | 29.5.2026 | 5,140 | +625 | $15.46 |
| Mabry Adam G | Tax Withholding in Shares | 29.5.2026 | 5,097 | -43 | $19.15 |
| Patadia Ankit B. | Grant/Award from Employer | 29.5.2026 | 9,047 | +1,358 | $15.46 |
| Patadia Ankit B. | Tax Withholding in Shares | 29.5.2026 | 8,953 | -94 | $19.15 |
| Moses Kelvin O | Grant/Award from Employer | 29.5.2026 | 1,692 | +937 | $15.46 |
| Moses Kelvin O | Tax Withholding in Shares | 29.5.2026 | 1,627 | -65 | $19.15 |
| Brinker Scott M | Gift | 14.5.2026 | 60,186 | +60,186 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
24,182,591 shares short as of 2026-08-31 · vs. 24,385,474 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
51.7% of trading volume this week was short selling, vs. 64.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology